Chronic kidney disease-associated pruritus is a persistent itching condition that affects many people living with advanced kidney disease, significantly impacting their sleep, mood, and daily quality of life. Treatment approaches range from self-care strategies and topical treatments to prescription medications and dialysis adjustments, with ongoing research exploring new therapies that target the underlying causes of this challenging symptom.

Understanding Treatment Goals for Kidney-Related Itching

Managing chronic kidney disease-associated pruritus requires a comprehensive approach focused on reducing discomfort and improving patients’ ability to sleep, work, and enjoy daily activities. This condition, which causes persistent itching without visible skin changes, presents unique challenges because the exact mechanisms behind it remain only partially understood. Treatment decisions depend on how severe the itching is, whether patients are on dialysis, and how they respond to initial interventions.^[2]

The primary goals of treatment include controlling the frequency and intensity of itching, preventing skin damage from scratching, and addressing the impact on mental health and sleep quality. Because approximately 30 to 70 percent of people with advanced kidney disease or those receiving dialysis experience this condition, medical societies recognize the importance of early identification and prompt treatment.^[3] Standard treatments approved by healthcare providers are available, and researchers continue investigating new therapeutic options through clinical trials to offer hope for those who don’t find relief with current methods.

Treatment typically begins with the simplest approaches and progresses to more complex interventions if symptoms persist. This stepwise strategy allows healthcare teams to balance effectiveness with potential side effects while tailoring care to each person’s specific situation and preferences.^[2]

Standard Treatment Approaches

Self-Care and Lifestyle Modifications

The foundation of managing kidney disease-related itching begins with simple self-care measures that patients can implement at home. These strategies focus on protecting the skin and reducing triggers that worsen itching. Keeping fingernails short helps prevent skin damage from scratching, which can lead to infections and increased inflammation in the skin. This is particularly important because scratching creates a cycle where it triggers more inflammation, which in turn causes more itching.^[4]

Clothing choices matter significantly in managing symptoms. Healthcare providers recommend wearing light, breathable cotton fabrics rather than irritating materials like wool. This allows the skin to remain cool, as heat can intensify itching sensations. Similarly, when bathing or showering, using lukewarm rather than hot water helps keep the skin from becoming overly dry.^[4]

Skin dryness is extremely common in people with kidney disease and is strongly associated with increased itching risk. To combat this, patients should avoid harsh soaps and perfumed cleansers that strip away the skin’s natural oils. Instead, using gentle soap substitutes and avoiding heavily fragranced products helps maintain the skin’s protective barrier.^[4]

Topical Treatments

Healthcare providers often recommend starting with topical treatments applied directly to the skin. Emollients, which are moisturizing creams and lotions, represent the first line of medical treatment for chronic kidney disease-associated pruritus. These products work by hydrating the skin and creating a protective layer that prevents moisture loss. Regular application of emollients can significantly improve skin condition and reduce itching intensity.^[2]

The effectiveness of topical treatments varies among individuals, but they offer the advantage of having minimal side effects compared to oral medications. Patients typically need to apply these products consistently, often multiple times daily, to maintain their benefits. Healthcare teams can provide guidance on which specific emollient formulations work best for different skin types and severity levels.

Prescription Medications

When self-care measures and topical treatments don’t provide adequate relief, doctors may prescribe oral medications that target the nervous system’s role in generating itch sensations. Gabapentin and pregabalin are medications originally developed to treat nerve pain, but they have shown effectiveness in reducing itching for some people with kidney disease. These drugs work by calming overactive nerve signals that the body interprets as itching.^[5]

The dosing of these medications requires careful adjustment based on kidney function, as people with chronic kidney disease process medications differently than those with healthy kidneys. Healthcare providers typically start with low doses and gradually increase them while monitoring for side effects. Common side effects can include dizziness, drowsiness, and fatigue, though not everyone experiences these effects.^[2]

Duration of treatment varies depending on individual response. Some people find relief within days to weeks, while others may need longer-term therapy. Regular follow-up appointments allow healthcare teams to assess effectiveness and make necessary adjustments to the treatment plan.

Phototherapy

Phototherapy, also called light therapy, involves exposing the skin to specific wavelengths of ultraviolet light under medical supervision. This treatment has demonstrated effectiveness in reducing chronic kidney disease-associated pruritus for some patients. The light therapy appears to work by affecting immune cells in the skin and reducing inflammation that contributes to itching sensations.^[5]

Phototherapy typically requires patients to visit a specialized facility multiple times per week for several weeks. The treatment sessions are relatively short, usually lasting just a few minutes. While generally safe, phototherapy does carry some risks, including potential skin damage with prolonged use, so careful monitoring by healthcare professionals is essential.

Dialysis Modifications

For people receiving dialysis treatment, adjustments to the dialysis process itself may help reduce itching. Healthcare providers can modify various aspects of dialysis, such as the type of dialyzer used, the composition of the dialysis solution, or the frequency and duration of sessions. These adjustments aim to improve the removal of toxins that may contribute to itching.^[5]

The relationship between dialysis adequacy and itching severity remains complex and not fully understood. However, ensuring optimal dialysis treatment represents an important component of overall symptom management. Patients should communicate openly with their dialysis team about when itching occurs in relation to their treatment schedule, as this information can guide beneficial adjustments.

Innovative Treatments in Clinical Trials

Kappa-Opioid Receptor Agonists

One of the most promising developments in treating chronic kidney disease-associated pruritus involves medications that target the body’s opioid receptors. Research has revealed that imbalances in how these receptors function may play a central role in generating itch sensations in people with kidney disease. Unlike opioid pain medications that can sometimes worsen itching, a newer class of drugs called kappa-opioid receptor agonists work differently by activating specific receptors that reduce itch signals traveling through the nervous system.^[2]

Difelikefalin, also marketed under the brand name KORSUVA Injection, represents a breakthrough in this therapeutic category. In 2021, the United States Food and Drug Administration approved this medication specifically for treating chronic kidney disease-associated pruritus in adults receiving dialysis. This approval marked the first time a therapy was specifically authorized for this condition, representing a significant milestone after years of limited treatment innovation.^[3]

Difelikefalin is administered intravenously at the end of each hemodialysis session, making it convenient for patients who are already receiving regular dialysis treatments. The medication works by selectively activating kappa-opioid receptors on immune cells and nerve fibers in the skin, which helps reduce the inflammatory signals and nerve activity that contribute to itching. Clinical trials testing this medication progressed through multiple phases to establish its safety and effectiveness.

In Phase II and Phase III clinical trials, difelikefalin demonstrated improvements in clinical parameters measuring itch severity. Patients receiving the medication reported reductions in itching intensity and improvements in sleep quality compared to those receiving placebo treatments. The trials also showed a positive safety profile, with the most common side effects being mild and including vomiting, diarrhea, and dizziness. These side effects were generally manageable and did not require most patients to discontinue treatment.^[9]

Another kappa-opioid agonist called nalbuphine has also been investigated for managing kidney disease-related itching. This medication can be administered orally or through other routes and works through similar mechanisms to reduce itch sensations. Research studies have explored its effectiveness in various patient populations, though it may not be specifically approved for this indication in all countries.^[5]

Understanding Clinical Trial Phases

The development of new treatments for chronic kidney disease-associated pruritus follows a structured research pathway through different phases of clinical trials. Phase I trials focus primarily on safety, testing new medications in small groups of participants to understand how the body processes the drug and what side effects might occur. These early studies help researchers determine appropriate dose ranges for further investigation.

Phase II trials expand the research to larger groups and begin evaluating whether the medication shows signs of effectiveness in reducing symptoms. These studies provide preliminary evidence about how well the treatment works while continuing to monitor safety. For chronic kidney disease-associated pruritus, Phase II trials typically measure changes in itch severity using standardized scales and assess impacts on quality of life and sleep.

Phase III trials represent the most rigorous testing phase before a medication can receive regulatory approval. These large-scale studies compare the new treatment against existing standard treatments or placebo to definitively establish effectiveness and safety. The trials for difelikefalin, for example, enrolled hundreds of dialysis patients across multiple countries to generate robust evidence supporting its approval.^[9]

Emerging Therapeutic Targets

Beyond opioid receptor modulation, researchers are investigating other innovative approaches based on growing understanding of what causes itching in kidney disease. Scientists are exploring the role of microinflammation, which refers to low-grade, persistent inflammation throughout the body that occurs in chronic kidney disease. This inflammation may trigger immune cells to release substances that activate itch-sensing nerves in the skin.^[2]

Studies are also examining abnormalities in how various chemical messengers function in patients with chronic kidney disease. Historical research investigated roles for substances like histamine (the chemical that causes itching in allergic reactions), parathyroid hormone, calcium, and magnesium. However, treatments targeting these factors have shown limited success, suggesting that the mechanisms behind kidney disease-associated itching are more complex than initially thought.^[2]

Newer research focuses on understanding how kidney disease affects peripheral nerves throughout the body, leading to a condition called peripheral neuropathy. When these nerves malfunction, they may send abnormal signals to the brain that are interpreted as itching even without any actual skin irritation. Medications and therapies that stabilize nerve function represent potential future treatment avenues.

Patient Eligibility for Clinical Trials

Clinical trials testing new treatments for chronic kidney disease-associated pruritus typically recruit participants with specific characteristics. Most studies focus on adults with advanced chronic kidney disease (Stages 4-5) or those receiving hemodialysis who experience moderate to severe itching. Trials usually require that itching has persisted for a minimum period, such as several weeks or months, and that other causes of itching have been ruled out.

Many trials exclude patients with certain medical conditions or those taking specific medications that might interfere with study results. Healthcare providers can help interested patients determine whether they might qualify for ongoing clinical trials. These trials take place in various locations, including research centers in the United States, Europe, and other regions, though availability varies depending on where a trial is actively recruiting.^[9]

Geographic Availability and Access

The availability of newer treatments like difelikefalin varies by country and region, as regulatory agencies in different locations evaluate medications independently. Following approval in the United States, medications may subsequently receive authorization in other countries after review by their respective regulatory bodies. Patients interested in accessing specific treatments should consult with their healthcare providers about what options are currently available in their area and what alternatives might be suitable if certain medications are not yet accessible locally.

Most Common Treatment Methods

• Self-Care Strategies
  • Keeping fingernails trimmed short to minimize skin damage from scratching
  • Wearing breathable cotton clothing instead of irritating fabrics like wool
  • Using lukewarm water for bathing rather than hot water
  • Avoiding harsh soaps and perfumed products that strip natural skin oils
  • Applying soap substitutes and gentle cleansers
• Topical Therapy
  • Regular application of emollients (moisturizing creams and lotions) to hydrate skin and create a protective barrier
  • Using non-perfumed skin products to avoid additional irritation
• Oral Medications
  • Gabapentin: A nerve pain medication that helps calm overactive nerve signals causing itching
  • Pregabalin: Another nerve pain medication with similar effects to gabapentin
  • Dosing adjusted based on kidney function with gradual increases as needed
• Phototherapy (Light Therapy)
  • Exposure to specific wavelengths of ultraviolet light under medical supervision
  • Multiple treatment sessions per week at specialized facilities
  • Works by affecting immune cells in skin and reducing inflammation
• Dialysis Modifications
  • Adjusting dialyzer type, dialysis solution composition, or treatment frequency
  • Optimizing dialysis adequacy to improve toxin removal
  • Timing adjustments based on when itching occurs relative to dialysis sessions
• Kappa-Opioid Receptor Agonists
  • Difelikefalin (KORSUVA Injection): Administered intravenously at the end of hemodialysis sessions
  • Nalbuphine: Available in oral or other formulations depending on country and approval status
  • Target specific receptors to reduce itch signals in the nervous system
• Kidney Transplantation
  • Not performed specifically for itching but can resolve symptoms by restoring kidney function
  • Nearly three out of four transplant recipients experience complete resolution of itching